/ZVSA
ZVSA Stock - ZyVersa Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$0.14-0.71%
$0.00 (-0.71%) • Dec 19
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.17
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.87
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.15
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ZVSA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.14 – $0.14
TARGET (TP)$0.16
STOP LOSS$0.13
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.81
52W High$1.95
52W Low$0.11
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-6,933 | $-10,400 | $-10,400 | $-10,400 | $-10,400 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-9,136,834,000 | $-14,420,774 | $-13,833,132 | $-7,704,376 | $-11,833,058 |
| Net Income | $-9,413,435,000 | $-98,297,946 | $-14,047,607 | $-8,084,161 | $-12,683,166 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-8.48 | $-1089.66 | $-930.25 | $-173.66 | $-272.45 |
Company Overview
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ZVSABeat Rate
57%
Last 7 quarters
Avg Surprise
-64.9%
EPS vs Estimate
Beats / Misses
4/3
Last 12 quarters
Latest EPS
$-0.15
Q4 2025
EPS Surprise History
Q1 24
-539.3%
$-13.68vs$-2.14
Q2 24
-22.4%
$-4.53vs$-3.70
Q3 24
+36.3%
$-3.31vs$-5.20
Q4 24
+58.1%
$-2.43vs$-5.80
Q1 25
+52.0%
$-1.31vs$-2.73
Q2 25
-82.5%
$-0.73vs$-0.40
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | — | — | — | — |
Q4 2025 | Nov 19, 2025 | — | $-0.15 | — | — |
Q3 2025 | Aug 13, 2025 | — | $-0.46 | — | — |
Q2 2025 | May 12, 2025 | $-0.40 | $-0.73 | -82.5% | ✗ MISS |
Q1 2025 | Mar 31, 2025 | $-2.73 | $-1.31 | +52.0% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-5.80 | $-2.43 | +58.1% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $-5.20 | $-3.31 | +36.3% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-3.70 | $-4.53 | -22.4% | ✗ MISS |
Q1 2024 | Mar 26, 2024 | $-2.14 | $-13.68 | -539.3% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-55.94 | $-31.47 | +43.7% | ✓ BEAT |
Q3 2023 | Aug 21, 2023 | — | $-1458.04 | — | — |
Q2 2023 | May 12, 2023 | — | $-0.39 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-184.55 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-80.34 | — | — |
Q3 2022 | Aug 15, 2022 | — | $-38.54 | — | — |
Q2 2022 | May 12, 2022 | — | $-78.69 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-68.72 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-40.38 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-45.00 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-45.97 | — | — |
Latest News
ZyVersa Therapeutics Q3 EPS $(2.56) Down From $(2.43) YoY
📉 NegativeBenzinga•Nov 20, 2025, 12:06 AM
Nasdaq To Delist Securities Of 10 Companies Including Lipella, ZyVersa, Crown LNG, Wag!, Ontrak, TPI Composites, And ModivCare Following Prior Suspensions
📉 NegativeBenzinga•Sep 24, 2025, 11:24 AM•Also: , ,
Frequently Asked Questions about ZVSA
What is ZVSA's current stock price?
ZyVersa Therapeutics, Inc. (ZVSA) is currently trading at $0.14 per share. The stock has moved -0.71% today.
What is the analyst price target for ZVSA?
No analyst price targets are currently available for this stock.
What sector is ZyVersa Therapeutics, Inc. in?
ZyVersa Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ZVSA's market cap?
ZyVersa Therapeutics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does ZVSA pay dividends?
No, ZyVersa Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCDT
CDT Equity Inc.
$1.63
Mkt Cap: $0.0B
ENVB
Enveric Biosciences, Inc.
$5.08
Mkt Cap: $0.0B
HEPA
Hepion Pharmaceuticals, Inc.
$0.07
Mkt Cap: $0.0B
INDP
Indaptus Therapeutics, Inc.
$2.03
Mkt Cap: $0.0B
JSPR
Jasper Therapeutics, Inc.
$1.86
Mkt Cap: $0.0B
NIVF
NewGenIvf Group Limited
$0.90
Mkt Cap: $0.0B
ONCO
Onconetix, Inc.
$1.77
Mkt Cap: $0.0B
SLXN
Silexion Therapeutics Ltd.
$2.40
Mkt Cap: $0.0B
WORX
SCWorx Corp.
$0.22
Mkt Cap: $0.0B
XAGE
Longevity Health Holdings Inc.
$0.43
Mkt Cap: $0.0B
Explore stocks similar to ZVSA for comparison